Summary
Pharmacokinetics of estradiol and estrone were assessed in postmenopausal women receiving S21400, a novel 17β-estradiol formulation administered by nasal route; the results were compared with those obtained with oral and transdermal routes. Thirty six women received three treatments: a specified dose of 17β-estradiol (100, 300 or 450 μg) given once and as 2 doses, 12 h apart, using three parallel dose groups in a randomised, crossover study. Thereafter, a reservoir patch (50 μg/day of 17β-estradiol) or a tablet of 2 mg micronised 17β-estradiol were randomly administered. Plasma concentrations of estradiol and estrone were measured by radioimmunoassays. Following intranasal dosing, estradiol was rapidly absorbed with plasma concentrations reaching maximal values (approximately 1400 pg/ml with a single 300 μg dose) after 10–30 min and returning within 12 h to levels of untreated postmenopausal women. Systemic exposure to estradiol was dose proportional and independent of the treatment regimen. Moreover, the dose of 300 μg gave an estimated 24 h systemic exposure to exogenous estradiol close to that of the 50 μg/day reservoir patch or the 2 mg tablet. The mean estrone to estradiol ratio was similar and 4-fold lower than those with the patch and the tablet, respectively. In conclusion, by this new route for estrogen replacement therapy, the nasal route, the pharmacokinetics of estradiol as S21400 were linear and displayed a ‘pulsed’ kinetic profile, different from those obtained with the usual routes of administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hargrove J.T., Eisenberg E. (1995): Menopause. Med. Clin. North Am., 79: 1337–1356.
Lievertz R.W. (1987): Pharmacology and pharmacokinetics of estrogens. Am. J. Obstet. Gynecol., 156: 1289–1293.
Judd H.L. (1987): Oestrogen replacement therapy: physiological considerations and new applications. Baillièrse’s Clin. Endocrinol. Metab., 1, 177–206.
Kuhnz W., Gansau C., Mahler M. (1993): Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Arzneimittelforschung, 43: 966–973.
Steingold K.A., Laufer L., Chetkowski R.J. et al. (1985): Treatment of hot flushes with transdermal estradiol treatment. J. Clin. Endocrinol. Metab., 61: 627–632.
Selby P.L., McGarricle H.H.G., Peacock M. (1989): Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin. Endocrinol., 30: 241–249.
McBurney E.I., Noel S.B., Collins J.H. (1989): Contact dermatitis to transdermal estradiol system. J. Am. Acad. Dermatol., 20: 508–510.
Hermens W.A., Belder C.W., Merkus J.M., Hooymans P.M., Verhoef J., Merkus F.W. (1991): Intranasal estradiol administration to oophorectomized women. Eur. J. Obstet. Gynecol. Reprod. Biol., 40: 35–41.
Peron P.G., Cladwell B.V. (Eds) (1970): Immunological methods in steroid determination. New York: Century-Crafts, 87–112.
Toutain P.L. (1995): QL-KINTOOL version 3.1. Pharmacokinetic software. Qualilab, 72, Quai du Châtelet, 45000 Orleans, France.
Yamaoka K., Nakagawa T., Uno T. (1978): Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165–175.
Berner B., John V.A. (1994): Pharmacokinetic characterisation of transdermal delivery systems. Clin. Pharmacokinet., 26: 121–134.
Marty J.P. (1996): New trends in transdermal technologies: development of the skin patch, Menorest®. Int. J. Gynecol. Obstet., 52: S17-S20.
Hankinson S.E., Willett W.C., Manson J.E. et al. (1995): Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J. Natl Cancer Inst., 87: 1297–1302.
Müller P., Botta L., Ezzet F. (1996): Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system. Eur. J. Clin. Pharmacol., 51:327–330.
Scott R.T., Ross B., Anderson C., Archer D.F. (1991): Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet. Gynecol., 77: 758–764.
Marty J-P. (1996): Menorest: technical development and pharmacokinetic profile. Eur. J. Obstet. Gynecol., 64: S29-S33.
Fink B.J., Christensen M.S. (1981): Bioavailability of oestradiol and oestriol administered orally to oophorectomized women. Maturitas, 3: 289–294.
Studd J., Pornel B., Marton I. et al. (1999): Dose-response study of the efficacy and acceptability of intra-nasal 17-β estradiol. Lancet, 353: 1574–1578.
Kronenberg F. (1990): Hot flushes: epidemiology and physiology. Ann. N. Y. Acad. Sci., 592: 52–86.
Kuttenn F. (1993): Traitement de la ménopause. Rev. Prat. (Paris), 43: 2593–2595.
Lindsay R., Dempster D.W., Jordan V.C. (Eds) (1997): Estrogens and antiestrogens: basic and clinical aspects. Philadelphia: Lapincott-Raven, 43–62.
Lobo R.A., Cassidenti D.L. (1992): Pharmacokinetics of oral 17β-estradiol. J. Reprod. Med., 37: 77–83.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Devissaguet, JP., Brion, N., Lhote, O. et al. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur. J. Drug Metab. Pharmacokinet. 24, 265–271 (1999). https://doi.org/10.1007/BF03190030
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190030